Aevi Genomic Medicine (GNMX) Tops Q4 EPS by 3c

Note: EPS may not be comparable

Aevi Genomic Medicine (NASDAQ: GNMX) reported Q4 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16).

Fourth Quarter 2017 Financial Results

• The Company had cash and cash equivalents of $33.73 million at December 31, 2017. The Company expects the current cash balance to fund operations into early 2019.
• Net research and development expenses for the three months ended December 31, 2017 were $5.26 million, increasing slightly from $5.14 million for the same period in 2016.
• General and administrative expenses for the three months ended December 31, 2017 were $1.90 million, decreasing from $3.35 million for the same period in 2016 mainly due to the closure of operations in Israel.
• For the quarter ended December 31, 2017 the Company reported a net loss of $7.16 million or $0.13 per share, compared with a net loss of $8.48 million or $0.23 per share for the comparative quarter in 2016.

For earnings history and earnings-related data on Aevi Genomic Medicine (GNMX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c